Kristen K. Ciombor

Also affiliated with Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade”.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Science(2017)10.1126/science.aan6733

N/A

1.3DataRank · unranked

6550 citations

Jennifer N. Durham, Kellie N. Smith, Hao Wang, Bjarne R. Bartlett, Laveet K. Aulakh +46 more

Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer

The Oncologist(2021)10.1002/onco.13741

N/A

0DataRank · unranked

48 citations

Subir Goyal, Yoanna S Pumpalova, Mohamad Bassam Sonbol, Satya Das, Sigurdís Haraldsdóttir +10 more

First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer

Journal of Nuclear Medicine(2021)10.2967/jnumed.120.261594

N/A

0DataRank · unranked

30 citations

Joe Grudzinski, Gary T. Smith, Todd E. Peterson, Jennifer G. Whisenant, Tiffany L. Hickman +9 more

A clinical score (CS) for patients with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177-dotatate.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.363

N/A

0DataRank · unranked

1 citations

Liping Du, Aimee Schad, Shikha Jain, Aaron Jessop, Chirayu Shah +9 more

Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4109

N/A

0DataRank · unranked

0 citations

Aman Chauhan, Liping Du, Katharine Thomas, Aasems Jacob, Aimee Schad +13 more

EA2201: An ECOG-ACRIN phase II study of neoadjuvant nivolumab plus ipilimumab and short course radiation in MSI-H/dMMR rectal tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3644

N/A

0DataRank · unranked

8 citations

Sung Chul Hong, Cathy Eng, Xin Yao, May Thet Cho, Y. Nancy You +4 more

Discovery and validation of a 10-gene predictive signature for response to adjuvant chemotherapy in stage II and III colon cancer

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101661

N/A

0DataRank · unranked

8 citations

Peng Xia, Jie Li, Keeli B. Lewis, Kristen K. Ciombor, Lily Wang +4 more

End-of-life (EOL) outcomes and healthcare utilization for patients with hepatocellular carcinoma (HCC) who received immune checkpoint inhibition (ICI).

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.4_suppl.560

N/A

0DataRank · unranked

0 citations

Anna-Carson Rimer Uhelski, Sarah K. Cimino, Henry J. Domenico, Sara Martin, Mohana Karlekar +5 more

End‐Of‐Life Outcomes and Healthcare Utilization for Patients With Hepatocellular Carcinoma Who Received Immune Checkpoint Inhibition

Cancer Medicine(2025)10.1002/cam4.71293

N/A

0DataRank · unranked

0 citations

Anna-Carson Rimer Uhelski, Sarah K. Cimino, Henry J. Domenico, Sara Martin, Mohana Karlekar +5 more

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

Molecular Oncology(2025)10.1002/1878-0261.70154

N/A

0DataRank · unranked

0 citations

Matthew A. Cottam, Muhammad Bilal Mirza, Keeli B. Lewis, Kristen K. Ciombor, M. Kay Washington +2 more